CHEMOTHERAPY FOUNDATION SYMPOSIUM XXVI
Tuesday, November 4 - Saturday, November 8
Marriott Marquis Hotel
New York City, USA

TUESDAY, NOVEMBER 4 • PEDIATRIC ONCOLOGY
Chair: Gustavo Del Toro, MD

1:30pm
  EASING OF SUFFERING IN CHILDREN WITH ADVANCED CANCER
  Joanne Wolfe, MD
1:45
  HEMATOPOIETIC CELL TRANSPLANTATION IN AML
  Elizabeth Roman, MD
2:00
 

UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION

  Vinod K. Prasad, MD
2:15
  JMML: DIAGNOSTIC AND TREATMENT CONSIDERATIONS
    Todd M. Cooper, DO
2:30
  NEW TRENDS IN PEDIATRIC HODGKIN'S LYMPHOMA
  Richard A. Drachtman, MD
2:45
  PEDIATRIC NON-HODGKIN'S LYMPHOMA
  Stan C. Goldman, MD
3:00
  Coffee Time
3:15
  CURRENT CLINICAL TRIAL FOR RHABDOMYOSARCOMA
  Douglas Hawkins, MD
3:30
 

LIMB-SPARING SURGERY FOR BONE SARCOMAS

  James Wittig, MD
3:45
  CHEMOTHERAPY FOR CHILDHOOD MALIGNANT BRAIN TUMORS
  James Garvin, MD
4:00
 

SIMULTANEOUS INTERRUPTION OF METABOLIC PATHWAYS IN CHILDHOOD ALL

  Julio C. Barredo, MD
4:15
  ADVANCES IN TREATMENT STRATEGIES IN PEDIATRIC ALL
  Stephen Sallan, MD
4:30
  Discussion
7 -9 pm
  DINNER AND SPECIAL PRESENTATION
  MEETING THE CLINICAL TRIAL CHALLENGES EMERGING FROM NOVEL BIOLOGICAL PLATFORMS
  Robet J. Arceci, MD, PhD
  PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
  Paul Gaynon, MD
   
  Election Results Live
   
  WEDNESDAY, NOVEMBER 5
7:00am
  BREAKFAST WITH THE PROFESSORS
    AN UPDATE OF ESAs IN ONCOLOGY
    Jeffrey Crawford, MD
  CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT
  James B. Bussel, MD
8:00
  WELCOME
  Steven Burakoff, MD, Janice L. Gabrilove, MD, Edward P. Ambinder, MD
  MORNING SESSION
  HEMATOLOGIC MALIGNANCIES
  Moderators: George F. Atweh, MD, Janet Cuttner, MD, Janice L. Gabrilove, MD
  MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS
  New Approaches and New Agents
8:10
  MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETS IN MPD
  Ronald Hoffman, MD
8:25
  JAK2 and MPL MUTATIONS
  Richard T. Silver, MD, FACS, Ayalew Tefferi, MD
8:40
  EPIGENETIC THERAPY IN MDS
  Hagop M. Kantarjian, MD
8:55
  VORELOXIN (SNS-595): AN ACTIVE AGENT IN AML
  Gail J. Roboz, MD
9:10
  THERAPY FOR POST-IMATINIB FAILURES
 

Jorge E. Cortes, MD

9:25
  APPROACH TO FRONT-LINE THERAPY IN CLL
  Kanti R. Rai, MD
9:40
  LENALIDOMIDE AND RITUXIMAB IN CLL
 

Asher Chanan-Kahn, MD

9:55
  FLAVOPIRODOL IN CLL
  Janice L. Gabrilove, MD
10:10
  Coffee Time
10:40
  LUMILIXIMAB STUDIES IN CLL
  Susan O'Brien, MD
10:50
  UPDATE on IMIDS in NHL
  Myron Czuczman, MD
11:00
  TARGETED THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMAS
  Ari Melnick, MD
11:15
  BORTEZOMIB AND LENALIDOMIDE-BASED TRIALS
  David H. Vesole, MD, PhD
11:30
  CARFILZOMIB: A NOVEL PROTEASOME INHIBITOR IN MYELOMA AND OTHER MALIGNANCIES
  Howard A. Burris, MD
11:45
  Discussion
12pm
  LUNCH AND PRESENTATIONS
  NEW DEVELOPMENTS IN MULTIPLE MYELOMA
  Role of Transplantation
  William Bensinger, MD
  Practical Applications of Clinical Trial Data
  Ravi Vij, MD
  AFTERNOON SESSION
1:15
  KEYNOTE ADDRESS
  DILEMMAS IN ADJUVANT THERAPY FOR EARLY BREAST CANCER: THE NSABP EXPERIENCE
  Norman Wolmark, MD
  GI CANCERS
  Moderators: Jordan D. Berlin, MD, Howard S. Hochster, MD,
Mace L. Rothenberg, MD
1:35
  MODIFIED DOCETAXEL-BASED REGIMENS FOR ADVANCED GASTROESOPHAGEAL CANCERS
  Jaffer Ajani, MD
1:50
  BIOMARKERS IN DECISION MAKING STAGE II COLON CANCER
  Anthony B. El-Khoueiry, MD
2:00
  NEW TYROSINE KINASE INHIBITORS FOR METASTATIC COLORECTAL CANCER
  Paulo M. Hoff, MD, FACP
2:15
  CAN CIRCULATING TUMOR CELLS BE A PREDICTIVE MARKER FOR TREATMENT OF COLON CANCER?
  Neal J. Meropol, MD
2:25
  SONIC HEDGEHOG: A NEW TARGET IN COLORECTAL CANCER?
  Mace L. Rothenberg, MD
2:40
  NEW PARADIGMS IN TREATMENT OF OXALIPLATIN NEUROTOXICITY
  Howard S. Hochster, MD
2:50
  REDUCING RISK OF RECURRENT COLON POLYPS
  Eugene W. Gerner, PhD
3:00
  Coffee Time
3:30
  MELPHALAN IN NON-COLORECTAL METASTASES TO THE LIVER
  James Pingpank, MD
3:40
  HEATED INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN METASTATIC GI MALIGNANCY
  Daniel M. Labow, MD
3:50
  PERSPECTIVES ON HIPEC THERAPY
  Elliot Newman, MD
4:00
  PANCREATIC CANCER: WHERE ARE WE GOING?
  Jordan D. Berlin, MD
4:15
  PHARMACOGENOMICS IN CANCER CLINICAL TRIALS
  Craig C. Lockhart, MD
4:30
  SMALL CELL CARCINOMA OF THE GI TRACT
  Heine Hansen, Professor, MD
4:45
  Discussion
7 - 9 pm
  DINNER AND PRESENTATIONS
  THERAPY OPTIONS FOR RITUXIMAB-REFRACTORY INDOLENT NHL
  John P. Leonard, MD
  BENDAMUSTINE AND OTHER TARGETED AGENTS IN NHL
  Ann S. LaCasce , MD
   
   
  THURSDAY, NOVEMBER 6
7:00am
  BREAKFAST WITH THE PROFESSORS
 

TARGETING VEGF RECEPTORS WITH PAZOPANIB: BIOLOGIC RATIONALE AND EMERGING CLINICAL DATA

  Mark D. Pegram, MD
  LAPATINIB: PREVENTING METASTATIC COLONIZATION OF BC CELLS IN THE BRAIN
  Diane Palmieri, MD, PhD
  MORNING SESSION
  Moderators: Franco M. Muggia, MD, Carmel Cohen, MD
  GYNECOLOGICAL CANCERS
8:00
  INTRAPERITONEAL THERAPY FOR OVARIAN CANCER: MISSION ACCOMPLISHED?
  Franco M. Muggia, MD
8:15
  CISPLATIN RESISTANT OVARIAN CANCER: OXALIPLATIN OR PACLITAXEL?
  Britta K. Stordal, MD
8:30
  VORELOXIN (SNS-595) IN PLATINUM-RESISTANT OVARIAN CANCER
  William P. McGuire, MD
8:45
  NOVEL INTRAPERITONEAL STRATEGIES FOR MANAGING PLATINUM RESISTANCE
  Stephen B. Howell, MD
9:00
  TRABECTEDIN IN RECURRENT OVARIAN CANCER
  Bradley J. Monk, MD
9:15
  NATIONAL AND INTERNATIONAL TRIALS IN OVARIAN CANCER
  William P. McGuire, MD
9:30
  HARNESSING THE IMMUNE SYSTEM FOR OVARIAN CANCER THERAPY
  KunIe O. Odunsi, MD, PhD
9:45
  EXPLOITING GENETIC DEFECTS WITH POLYMERASE INHIBITORS
  Hilary Calvert, MD
10:00
  Discussion
10:15
  Coffee Time
  BRAIN
10:45
  UPDATE: PHASE II TRIAL OF CEDIRANIB IN RECURRENT GLIOBLASTOMA
  Elizabeth R. Gerstner, MD
  NEUROENDOCRINE
11:00
  ATIPRIMOD PHASE II TRIAL FOR NEUROENDOCRINE CANCER
  Max Sung, MD
  SARCOMA
11:15
  ORAL DEFOROLIMUS IN METASTATIC SOFT-TISSUE AND BONE SARCOMAS
  George Demetri, MD
11:30
  INTRAVENOUS REOLYSIN IN BONE OR SOFT TISSUE SARCOMA METASTIC TO LUNG
  Monica M. Mita, MD
11:45
  Discussion
12 Noon
  LUNCH AND PRESENTATIONS
  ADVANCES IN HCC THERAPY
  Josep M. Llovet, MD
  OVERVIEW OF ASIAN DATA ON HCC
  Bert O'Neil, MD
  AFTERNOON SESSION
  BREAST CANCER
1:30
  EZRA M. GREENSPAN MEMORIAL LECTURE
 

INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT

  Howard A. Burris, MD
 

Moderators: Seymour Cohen, MD, Larry Norton, MD,
George Raptis, MD

1:50
  THE SELF-SEEDING MODEL OF CANCER: CLINICAL IMPLICATIONS
  Larry Norton, MD
2:05
  NEW ASSAYS TO DETERMINE HER2 STATUS
  Allen Lipton, MD
2:20
  FULVESTRANT: WHAT HAVE WE LEARNED FROM USING HIGHER DOSES?
  Irene Kuter, MD, PhD
2:35
  COMBINED ANTI-HER2 THERAPY: TRASTUZUMAB AND LAPATINIB
  Harold Burstein, MD, PhD
2:50
  TRASTUZUMAB-DM1, A NOVEL APPROACH TO THE TREATMENT OF HER2+ BREAST CANCER
  Ian E. Krop, MD PhD
3:05
  Coffee Time
3:35
 

LAPULEUCEL-T IN IMMUNOTHERAPY OF BREAST CANCER: CLINICAL TRIAL DATA

  John Park, MD
3:50
  HER2 VACCINATION IN HIGH RISK BREAST CANCER
 

George E. Peoples, MD, FACS

4:05
 

PROTEASOME INHIBITOR ENHANCES HORMONAL THERAPY IN BREAST CANCER

  Samuel Waxman, MD
4:20
  Discussion
  THYROID
4:35
  TREATMENT OF IODINE-RESISTANT ADVANCED THYROID CANCER
  Marcia Brose, MD, PhD
  HEAD AND NECK
4:45
  OVERCOMING IMMUNOSUPPRESSION IN HEAD AND NECK CANCER WITH CITOPLURIKIN (IRX-2)
  Jeffrey S. Moyer, MD
4:55
  Discussion
7 - 9pm
  DINNER AND PRESENTATIONS
  PERSONALIZED MEDICINE: TREATMENT DECISION-MAKING
  Norman Wolmark, MD, Harold Burstein, MD, PhD
     
     
  FRIDAY, NOVEMBER 7
7:00am
  BREAKFAST WITH THE PROFESSORS
 

THE CONTROVERSY: ARE ANTHRACYCLINES NECESSARY FOR EARLY BREAST CANCER?

  Stephen E. Jones, MD
  UPDATE ON CHEMOTHERAPY FOR ADVANCED BREAST CANCER
  Stephen Y. Chan, MD
  MORNING SESSION
  URO-ONCOLOGY
 

Moderator: Anna C Ferrari, MD

  PROSTATE
8:00
  ENDOTHELIAL A: SURVIVAL AND BONE METASTASES IN HRPC
  Nancy A. Dawson, MD
8:15
  VACCINE APPROACHES IN EARLY STAGE PC
  Robert S. DiPaola, MD
8:30
  ABIRATERONE ACETATE: AN ANDROGEN WITHDRAWAL RESPONSIVE PHENOTYPE IN CRPC
  Eleni Efstathiou, MD, PhD
  RENAL
8:45
 

DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS

  Roberto Pili, MD
8:55
  PHARMACODYNAMIC TRIAL OF FLT-PET/CT IMAGING IN SUNITINIB-TREATED RENAL CELL CARCINOMA
  Glenn Liu, MD
9:10
  Discussion
  LUNG CANCER
 

Moderator: Roman Perez-Soler, MD, Marc Ballas, MD

9:25
  ROLE OF MAINTENANCE THERAPY IN ADVANCED NSCLC
  Chandra P. Belani, MD
9:40
  EGFR INHIBITORS IN NSCLC AND HOW TO SELECT PATIENTS
  Fred Hirsch, MD, PhD
9:55
  EVOLVING ROLE OF SUNITINIB IN NSCLC
  Mark A. Socinski, MD
10:05
  Coffee Time
10:20
  TALACTOFERRIN IN REFRACTORY NSCLC
  Giuseppe Giaccone, MD, PhD
10:30
  PERSONALIZED THERAPY APPROACHES FOR ADVANCED NSCLC
  Roy S. Herbst, MD, PhD
10:45
  THIRD LINE THERAPY FOR NSCLC AND BEYOND
  Cory Langer, MD
11:00
  PHASE II STUDY OF PICOPLATIN FOR 2ND LINE SCLC
  John R. Eckhardt, MD
11:10
  UPDATE ON AMRUBICIN IN SCLC
  Robert M. Jotte, MD, PhD
11:20
  PHASE I/II STUDY OF DOCETAXEL PLUS OBATOCLAX (GX17-070) IN RELAPSED NSCLC
  Alberto A. Chiappori, MD
11:30
  MAG3 VACCINATION FOR LUNG CANCER
  Nasser Altorki, MD
11:40
  LUNG CANCER VACCINE L-BLP25
  Nevin Murray, MD
11:50
  Discussion
12 Noon
  LUNCH AND PRESENTATIONS
  EVEROLIMUS FOR RENAL CELL CARCINOMA
  Robert J. Motzer, MD
  ASA-404: A NOVEL VASCULAR DISRUPTING AGENT FOR LUNG CANCER THERAPY
  Primo N. Lara Jr., MD
  AFTERNOON SESSION
1:15
  JUDAH FOLKMAN MEMORIAL LECTURE
  IMMUNE THERAPY FOR OVARIAN CANCER: ARE WE READY TO LAUNCH?
  George Coukos, MD, PhD
  DIVERSE THERAPEUTICS
 

Moderators: Edward Ambinder, MD, Sylvia Adams, MD,
Jorge Gallardo, MD

  MELANOMA
1:35
  STAGING AND PROGNOSTIC CRITERIA
  Charles Balch, MD
1:50
  SYSTEMIC ADH-1 AND MEPHALAN ILI IN ADVANCED EXTREMITY
  Douglas S. Tyler, MD
2:05
  THE EVOLUTION OF OBLIMERSEN
  Anna Pavlick, MD
  IMMUNOTHERAPY
2:15
  RADIOTHERAPY WITH IMMUNOTHERAPY
  Silvia Formenti, MD
  SOLID TUMORS
2:25
  NOVEL ANTICANCER AGENTS IN THE NCI CTEP CLINICAL DEVELOPMENT PROGRAM
  John J. Wright, MD, PhD
2:40
  AMG386: A FIRST-IN-CLASS ANGIOPOIETIN TARGETED THERAPY
  Alain C. Mita, MD
2:50
  TERAMEPROCOL INFUSION FOR REFRACTORY SOLID TUMORS
  Jeffrey Infante, MD
3:00
  Coffee Time
3:15
  ENILURACIL: CLINICAL UPDATE ON NOVEL SCHEDULES WITH A DPD-INHIBITOR
  Howard A. Burris, MD
  OTHER CLINICAL OPTIONS
3:25
  EVALUATION OF MLN 8237: A NOVEL AURORA A KINASE INHIBITOR
  E. Claire Dees, MD
3:35
  RECENT DATA FROM THE Z-FAST AND ZO-FAST TRIALS
  Allan Lipton, MD
3:45
  AERODIGESTIVE CANCER PREVENTION
  Alex Adjei, MD
4:00
  GENERIC TREATMENT PLAN TEMPLATE
  Joseph Jacobson, MD
4:15
  LATE BREAKING DEVELOPMENTS
4:45
  Discussion
7 -9pm
  DINNER AND PRESENTATIONS
  CHANGING PARADIGMS IN THE THERAPEUTIC APPROACH TO ADVANCED NSCLC
  Mark Socinski, MD
  CETUXIMAB IN NSCLC
  Thomas J. Lynch, MD
   
   
  SATURDAY, NOVEMBER 8
  NEW PERSPECTIVES IN ONCOLOGY PRACTICE
7:00am
  Registration & Continental Breakfast
8:00
  OPENING REMARKS
  Shannon Holloway, MHS, PA-C (Co-Chair) • Andrea Downey, BSN, MA, AOCN (Co-Chair)
8:10
  NOVEL THERAPEUTICS FOR MELANOMA
  Anna Pavlick, DO
8:30
  WHEN YOUR PATIENT DIES: PERSONAL GRIEF IN THE PROFESSIONAL SETTING
  Nora Rightmer, LCSW
8:50
  MYELODYSPLATIC SYNDROME: SUPPORTIVE CARE TO ACTIVE TREATMENT
  Sandra Allen-Bard, BSN, MSN, APN-C, AOCNP
9:10
  MAKING THE LAW WORK FOR YOU AND YOUR PATIENT: DOCUMENTING & PRESCRIBING CONTROLLED SUBSTANCES
  Jennifer Bolen, JD
9:35
  NEW ADVANCES IN mTor THERAPY
  Andrea Rustine, PA-C
9:55
  CHEMOBRAIN & COGNITIVE FUNCTION
  Lynne Wagner, PhD
10:15
  BREAK
10:35
  KEYNOTE ADDRESS
  DEALING WITH EMOTIONS, STRENGTHENING RELATIONSHIPS
  Robert Buckman, MD
11:05
  THE CHANGING PRACTICE MANAGEMENT ENVIRONMENT
  Joseph Bailes, MD
11:25
  TRANSPLANT-RELATED INFECTIONS: THE CHALLENGE CONTINUES
  Angela Johns, RN, MPA, ANP
11:45
  USE OF METHADONE IN CANCER TREATMENT
  Nessa Coyle, PhD, NP
12:05
  LUNCH
1:15
  VIDEO: CANCER THROUGH THE EYES OF THE PATIENT AND FAMILY
  Teresa Gilewski, MD
1:40
  PATIENT-CENTRIC QUALITY ONCOLOGY CARE
  Edward Ambinder, MD
2:00
  EMERGING TRENDS IN MULTIPLE MYELOMA TREATMENT
  Faiza Zafar, PA-C
2:20
  PALLIATIVE INTERVENTIONS IN THE ONCOLOGY WORLD
  Christopher Comfort, MD
2:40
  ADHERENCE TO THERAPY: IT MAY BE A BIGGER ISSUE THAN YOU REALIZE
  Cathy Maxwell, RN, OCN
3:00
  TRENDS IN THE MANAGEMENT OF COLORECTAL CANCER
  Shannon Holloway, MHS, PA-C
3:40
  EMERGING TRENDS IN THE MANAGEMENT OF VTE IN CANCER PATIENTS
  Edith Nutescu, PharmD
4:00
  CLOSING REMARKS
  Shannon Holloway, MHS, PA-C (Co-Chair) • Andrea Downey, BSN, MA, AOCN (Co-Chair)

 

Schedule of Sessions

Tuesday, Nov 4, 1:30pm - 5:00pm, Pediatric Oncology
Wednesday, Nov 5, 7:00am - 5:00pm, Hematology & GI Cancers
Thursday, Nov 6, 7:00am - 5:00pm, GYN and Breast Cancers
Friday, Nov 7, 7:00am - 5:00pm, GU, Lung, Melanomas, Brain, Sarcoma, Solid Tumors, Other
Saturday, Nov 8, 7:00am - 4:00pm, Program for Non-Physician Cancer Care Providers

Americans with Disabilities Act: Mount Sinai School of Medicine is in full compliance with provisions of the Americans with Disabilities Act (ADA). If you would like to attend this conference and require any special needs or accommodations, please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.